The separation of the pneumococci previously included in Group IV into serologically specific types (1) has made possible the accurate identification of nearly all pneumococci. In this paper will be presented the result of studies on the specific antibody response of human subjects to infections associated with these newly classified types of pneumococci. Similar studies in patients with 2 important pairs of immunologically related types of pneumococci, namely, Types III and VIII and Types II and V, have been reported in the preceding communications (2, 3) and only a summary of these results are included here for comparison.
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The sera of 190 patients with infections associated with pneumococci other than Type I were studied. The number of patients and sera in each of 3 kinds of cases studied are listed in Table I according to the type of pneumococcus obtained. The "non-pneumonias " include patients with acute and chronic respiratory infections, but without pulmonary consolidation, and those with purulent focal infections. The methods employed were the same as those used in the previous studies (2) .
Agglutinins for pneumococci of the homologous type Agglutinins for the homologous type of pneumococcus were demonstrated in the sera of two-thirds of the patients with lobar or bronchopneumonia associated with Types II and III and with 9 of the newly classified types (see Table II ). The data for the individual patients in whose sera such antibodies were demonstrated are shown in Table III and  in the corresponding tables in the previous papers (2, 3 ). Also, 6 of the 22 fatal cases showed agglutinins for the homologous type in the serum before death.
The titer of the agglutinins for the newly-classified types was comparable with that found in similar patients with Types I, II and III pneumococcus pneumonia (4) . Sera which agglutinated one strain of a given type also agglutinated all other strains of the same type to approximately the Patients Num-Num-Num-Num-Num-Num-Num-Num-Num-Number ber ber ber ber ber ber ber ber ber of pa-of of pa-of of pa-of of pa-of of pa-of tients sera tients sera tients sera tients sera tients sera 
Results of mouse protection tests
Attempts to enhance sufficiently the virulence of a number of strains of the new types of pneumococci for use in protection tests proved unsuccessful, except with Types V and VIII. Virulent strains of Types IV, VII and XVIII pneumococci, however, were obtained through the kindness of Miss Georgia Cooper. Protection tests were carried out on the sera of most of the patients with pneumonia from whom these types were obtained. The results of similar tests with Types III and VIII and Types II and V have already been reported (2, 3) .
The results of the protection tests paralleled, in general, the findings of agglutinins (Table III) . Occasional sera showed mouse-protection in the absence of agglutinins for the same type. The titer of antibodies was similar to that observed with the common types.
Mixed infections
In Table VI are listed 12 patients with pneumonia from whom 2 or more organisms, chiefly pneumococci, were isolated. The presence or Agglutinins and mouse protection in normal subjects The sera of 26 hospital patients without recent infection or previous history of pneumonia and laboratory workers were tested for agglutinins with all of the types of pneumococci encountered in this investigation. Tests for mouse protection were carried out with Types I, II, III, IV, V, VII and VIII pneumococci. Agglutinins were found in only 2 in- Type VIII in 3 subjects. In 6 of the subjects the serum protected against as much as 100,000 lethal doses of Type VII pneumococci. There was no correlation between the presence of protection for any one type and that against any other. These results correspond to those previously obtained with some of these types (5).
DISCUSSION
Strains of pneumococci formerly included in Group IV are found in the nose and throat of most normal individuals (6) and may be obtained, with proper methods, from some patients with pneumonia in whom the Type I or II pneumococcus is the probable invader (7). They are usually less virulent for animals than are strains of Type I and II. Their relationship to lobar pneumonia, therefore, has been doubted (7), especially to verify the antigenic, and, therefore, also the probable etiologic relationship of the newly classified types of pneumococci to the diseases with which they are associated, (2) to determine the specificity of this relationship, (3) to determine whether, in cases where the serum fails to react with the homologous type, another pneumococcus, not recovered from the patient by the ordinary methods, was responsible for the infection, and (4) to shed some light on the significance of the finding of more than one type in the same patient.
The results of these tests and of the absorption experiments indicate that, in most instances, these newly classified types of pneumococci are comparable to Types I and II in their antigenic relationship to the diseases in which they are found. The rarity with which Types I and II antibodies were demonstrated in these cases is worthy of note, since every serum was tested with these types. These types cannot be considered the exclusive causes of lobar pneumonia.
Protective antibodies, frequently of high titer, against some types of pneumococci, were demonstrated in many normal individuals. These findings, however, do not vitiate the results obtained in the pneumonia patients, since only the latter showed agglutinins and since the tests early in the disease were usually negative.
SUMMARY AND CONCLUSIONS
Two-thirds of the recovered pneumonia patients with 11 different types of pneumococci, including 9 of the newly classified types (Cooper) , were found to have antibodies for the homologous type of pneumococcus. The results were similar in the patients with bronchopneumonia and those with lobar pneumonia. A number of fatal patients also had such antibodies late in the disease. Occasional patients with acute respiratory infections, without demonstrable pneumonia, also showed antibodies for the type of pneumococcus recovered from their sputa.
The specificity of the immune response was demonstrated by the failure, in such instances, to find antibodies for the other common types and by the specific absorption of the antibodies with pneumococci of the homologous and not the heterologous type.
A few cases were found to have antibodies against types other than the one isolated from the patient's sputum. Most of these represented crossagglutinations with related types, particularly Types III and VIII.
In the patients in whom more than one type of pneumococcus was isolated, immunity was usually present against only one of these.
These findings tend to confirm the biological identity of the newly classified types of pneumococci. They lend further support to the etiological relationship of these types to the acute pulmonary infections with which they are associated.
